Company Filing History:
1 out of 282 
1 out of 832,880 Years Active: 2007
Title: **Masahiko Hibi - Pioneer in Cytokine Receptor Research**
Introduction
Masahiko Hibi is an accomplished inventor based in Kobe, Japan, known for his significant contributions to the field of biomedical research. With a focus on cytokine receptor malfunction, his innovative work has paved the way for potential therapeutic strategies in treating diseases linked to this critical pathway. His expertise and dedication to research have led to the development of a groundbreaking patent.
Latest Patents
Hibi holds a patented invention titled "Method of screening for substance preventing or treating diseases in association with malfunction of IL-6 family cytokine receptor malfunction." This invention describes a method that employs a transgenic mouse or its components, which express a gp130 variant. The innovation specifically targets alterations in the gp130 protein that correlate with human disease mechanisms, aiming to identify substances that could prevent or treat associated illnesses.
Career Highlights
Throughout his career, Masahiko Hibi has worked with notable organizations, including Santen Pharmaceutical Co., Ltd. His role in these firms has allowed him to collaborate on significant research projects, contributing to advancements in medical therapeutics. His dedication to pushing the boundaries of scientific knowledge in cytokine receptor biology has marked him as a prominent figure in the industry.
Collaborations
Hibi has collaborated with fellow researchers Toshio Hirano and Katsuhiko Ishihara. These partnerships have fostered innovative discussions and shared knowledge, ultimately leading to advancements in the understanding of cytokine interactions and their implications in health and disease.
Conclusion
Masahiko Hibi's work exemplifies the intersection of scientific inquiry and practical application in medicine. Through his patented invention and collaborations, he continues to impact the field of medical research significantly. His ongoing efforts lay the foundation for future breakthroughs in the understanding and treatment of diseases linked to cytokine receptor malfunctions.